Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: A nationwide descriptive study
Miguel García‐Grimshaw, Santa Elizabeth Ceballos‐Liceaga, Laura E. Hernández‐Vanegas, Isaac Núñez, Noé Hernández-Valdivia, Daniel Amado Carrillo-García, Anaclara Michel‐Chávez, Javier Andrés Galnares‐Olalde, Guillermo Carbajal‐Sandoval, María del Mar Saniger‐Alba, Roger Carrillo‐Mezo, Sergio Fragoso-Saavedra, Alba Espino-Ojeda, Carlos Blaisdell-Vidal, Juan Luis Mosqueda-Gómez, Juan Sierra‐Madero, Rogelio Pérez‐Padilla, José Luis Alomía-Zegarra, Hugo López‐Gatell, José Luis Díaz‐Ortega, Gustavo Reyes‐Terán, Antonio Araúz, Sergio Iván Valdés‐Ferrer
Topics & Concepts
MedicineObservational studyAdverse effectIncidence (geometry)Coronavirus disease 2019 (COVID-19)ImmunizationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Vaccine safety2019-20 coronavirus outbreakPediatricsInternal medicineEmergency medicineVirologyImmunologyAntibodyDiseaseInfectious disease (medical specialty)PhysicsOpticsOutbreakSARS-CoV-2 and COVID-19 ResearchPeripheral Neuropathies and DisordersLong-Term Effects of COVID-19